Sanofi India receives order for ₹2.86 Crore tax demand and penalty
Sanofi India Limited received an order from CGST & Central Excise, Mumbai, for FY 2018-19 to FY 2022-23. The order includes a tax demand of ₹1,43,49,690, a penalty of ₹1,43,49,690, and interest for wrong availment/utilization of Input Tax Credit. The company intends to appeal the order.
The tax demand and penalty amount to ₹2.86 crore, which could impact the company's financials, although the company plans to appeal, potentially mitigating the impact.
The company has received an order for a significant tax demand and penalty, which is a negative development.
Sanofi India Limited has received an order from the Principal/Joint Commissioner of CGST & Central Excise, Mumbai. The order pertains to the period FY 2018-19 till FY 2022-23 and determines a tax demand of ₹1,43,49,690, a penalty of ₹1,43,49,690, and applicable interest under the CGST and IGST Act, 2017.
The alleged contravention relates to the wrong availment and utilization of Input Tax Credit (ITC). The order was dated 29th December 2025 and received by the company on the same date.
The company plans to appeal this order before the Higher Tax Authorities. The total quantifiable impact in monetary terms amounts to ₹2,86,99,380 (tax demand and penalty combined), excluding applicable interest.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.